Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized withdrawal study of LCI699 in Cushing's disease
NL-OMON47814Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of osilodrostat in Corticotropin adenoma (ACTHoma) (3 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Aug 2015; status: recruiting.
02
Drugs
osilodrostat
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on NL-OMON47814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47814.